NAVB
Resultados positivos de fase III. La noticia parece consistente. Me acabo de subir con un puñaíco en after con bastante riesgo en cualquier caso.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
GWPH , menudo run up se ha cascado en 2,5 meses, la virgen!
https://www.google.com/finance?q=gwph&ei=VTlTUuD3IZTEwAPF9wE
Lazard sees huge potential in GW Pharmaceuticals' epilepsy program
- Lazard is excited about Sativex maker GW Pharmaceuticals (GWPH).
- Market chatter suggests Joshua Schimmer has raised his price target on the shares to $65 (from $22) for upside potential of 163%.
- Apparently, the company's Otsuka-partnered (OTSKF.OB) epilepsy program is "one of the most compelling opportunities [Lazard] has ever seen."
- Here's what the company has to say about that program: "By studying the impact of cannabinoid addition on the amplitude of the epileptiforms produced, researchers are able to recognize if compounds could perform as an anti-epileptic drug in vivo."
---------
Es curioso como de algunas farmas no oimos hablar y suben de una manera acojonante y otras, de las que nos hablan a diario, estan tan mediatizadas, manipuladas y puteadas que cuesta ganarse cada centavo con ellas.
Confirman finalmente con un estudio de ocho años que el resveratrol del tintorro es anticancerígeno, incluso después de metabolizado, y abre una nueva vía de investigación oncológica.
«Después de nada, o después de todo/ supe que todo no era más que nada.»
DCTH
La subida parece ser por el recorte de la plantilla en 1/3 del personal tras la cagada con la FDA.
"This week's job cuts, however, have nearly doubled the value of Delcath's stock. The company traded at about 59 cents Monday morning"
«Después de nada, o después de todo/ supe que todo no era más que nada.»
New AGENUS.....
GSK’s Vaccine Candidate Containing Agenus’ QS-21 Stimulon® Reduces Malaria Infection in Phase 3 Trials of Over 15,000 Ch...
Print
Alert
Antigenics (NASDAQ:AGEN)
Intraday Stock Chart
Today : Tuesday 8 October 2013
Click Here for more Antigenics Charts.
Significant protection shown 18 months post vaccination
RTS,S vaccine could have a major public health impact on malaria in Africa
GSK plans regulatory submission in 2014
Agenus entitled to receive milestone payment and royalties upon launch
Agenus Inc. (NASDAQ: AGEN) today announced that new Phase 3 data for GlaxoSmithKline’s (NYSE: GSK) RTS,S malaria vaccine candidate, which contains Agenus’ QS-21 Stimulon®1 adjuvant, were presented at a Multilateral Initiative on Malaria Pan African Conference in Durban, South Africa. The abstract and presentation titled, “Efficacy of RTS,S/AS01 vaccine candidate against malaria in African infants and children 18 months post-primary vaccination series: a Phase 3 randomized, double-blind controlled trial,” shows that RTS,S helped protect young children and infants from clinical malaria up to 18 months post vaccination. RTS,S is the most advanced malaria vaccine candidate in the world and the first vaccine candidate to show in clinical trials that it can help protect young children and infants living in malaria-endemic areas against clinical disease and infection caused by Plasmodium falciparum. Malaria claims over 600,000 lives a year, most of which are children in Sub-Saharan Africa.2
Ayer entré en AGEN a a 2,78.....
A ver si pega un buen estirón y me la cepillo hoy mismo....
Estas son las operaciones que me encantan...
15-20% en pocos días y a por otra....
Un saludo
Buen momento para estas publicaciones, si señor, parece ser que lo que trata de descubrir REDUCE-IT ya se sabe y esta ampliamente probado, :))
Discovery and refinement of loci associated with lipid levels
http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.2797.html
Massive DNA study points to new heart drug targets and a key role for triglycerides
http://www.ns.umich.edu/new/releases/21728-massive-dna-study-points-to-new-heart-drug-targets-and-a-key-role-for-triglycerides
AMRN
